Brigham & Women's aligns with GE for molecular imaging research
GE Healthcare has signed a research agreement with Brigham & Women's Hospital (BWH), a 777-bed teaching affiliate of Harvard Medical School in Boston, to establish a PET molecular imaging center, which will house a GE cyclotron for the development of PET radiopharmaceuticals.
Clinicians and scientists from both BWH and GE plan to use the tools of molecular imaging and radiopharmaceutical development to develop personalized approaches to the diagnosis and management of patients with oncologic, neurologic and cardiovascular diseases.
"The collaboration of GE Healthcare's resources in chemistry, biology, drug development, engineering and imaging technology with BWH's strengths in clinical research creates a partnership with unlimited potential to improve the care of patients," said Steven Seltzer, MD, chairman of the radiology department at BWH.
"The more we understand about disease from a clinical standpoint, the better equipped we are to build technologies to improve patient care," said Jean-Luc Vanderheyden, GE's global molecular imaging leader. "This collaboration has the ability to accelerate the process of developing more effective methods of diagnosing, treating and monitoring disease."
Clinicians and scientists from both BWH and GE plan to use the tools of molecular imaging and radiopharmaceutical development to develop personalized approaches to the diagnosis and management of patients with oncologic, neurologic and cardiovascular diseases.
"The collaboration of GE Healthcare's resources in chemistry, biology, drug development, engineering and imaging technology with BWH's strengths in clinical research creates a partnership with unlimited potential to improve the care of patients," said Steven Seltzer, MD, chairman of the radiology department at BWH.
"The more we understand about disease from a clinical standpoint, the better equipped we are to build technologies to improve patient care," said Jean-Luc Vanderheyden, GE's global molecular imaging leader. "This collaboration has the ability to accelerate the process of developing more effective methods of diagnosing, treating and monitoring disease."